Hippo-YAP Pathway for Predictive Cancer Biomarkers


Many human cancers harbor genetic aberrations in the Hippo-YAP pathway. Previously however, there was no clear connection between alterations in this pathway and the etiology, progression, or treatment of tumors. Researchers in the laboratory of Professor Marc Kirschner at Harvard Medical School have identified Hippo-YAP signaling pathway as a mediator of cancer cell sensitivity to chemotherapeutics and a predictor of patient response and survival. Their findings positions the Hippo-YAP pathway as a potent source of novel pan-cancer predictive biomarkers and drug targets for adjuvant chemosensitizers. This technology is available for licensing or a collaborative project with molecular diagnostics and drug development companies.

Intellectual Property Status: Patent(s) Pending